Recent Advances of Epigallocatechin Gallate (EGCG)on Oral Cancer

doi:10.3969/j.issn.1005-4979.2018.03.010

Abstract

Abstract: Epigallocatechin gallate (EGCG) is a major polyphenolic compound extracted from green tea. Many researches showed that it can not only be used as a health product preventing the happening of oral cancer, but also aim at the key factors of signaling pathways, thereby promoting the apoptosis of oral cancer cells and inhibiting the proliferation, migration, invasion of oral cancer and controling the development. This paper aimed to review the advances on anti-oral cancer effect mechanism of EGCG, to provide thought for following-up research of molecular mechanism on oral cancer and molecular targeted therapy of anti-oral cancer drugs.

Key words: EGCG, oral cancer, signal pathway, mechanism

摘要： 表没食子儿茶素没食子酸酯（epigallocatechin gallate，EGCG）是绿茶提取物中的主要活性成分。大量研究表明，它不仅可以作为保健品预防口腔癌的发生，而且可以作用于信号通路中的关键效应因子，从而促进口腔癌细胞的凋亡，抑制其增殖、迁移、侵袭，进而控制口腔癌的发展。本文就近年来国内外关于EGCG作用于口腔癌细胞的分子机制研究进展做了综述，旨在为其抗口腔癌分子机理的后续研究，口腔癌的药物靶向治疗提供思路。

关键词: 表没食子儿茶素没食子酸酯, 口腔癌, 信号通路, 分子机制

CLC Number:

R732.2
R782

LI Ao-nan1,2, GU Ke1,2, WEN Yong1,2. Recent Advances of Epigallocatechin Gallate (EGCG)on Oral Cancer[J]. 《Journal of Oral and Maxillofacial Surgery》, doi: 10.3969/j.issn.1005-4979.2018.03.010.

李傲楠1,2，顾客1,2，文勇1,2. EGCG对口腔癌细胞的作用及其分子机制研究进展[J]. 《口腔颌面外科杂志》, doi: 10.3969/j.issn.1005-4979.2018.03.010.

/ / Recommend / Download Citations

URL: https://journal06.magtech.org.cn/Jweb_joms/EN/10.3969/j.issn.1005-4979.2018.03.010

https://journal06.magtech.org.cn/Jweb_joms/EN/Y2018/V28/I3/172

References

[1] Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016[J]. CA: A Cancer Journal for Clinicians, 2016, 66(4):271-289.

[2] Parikh P, Patil V, Agarwal JP, et al. Guidelines for treatment of recurrent or metastatic head and neck cancer[J]. Indian J Cancer, 2014, 51(2):89-94.

[3] Chen ZM, Lin Z. Tea and human health: biomedical functions of tea active components and current issues[J]. J Zhejiang Univ Sci B, 2015, 16(2):87-102.

[4] Gan RY, Li HB, Sui ZQ, et al. Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review[J]. Crit Rev Food Sci Nutr, 2018, 58(6):924-941.

[5] Ramshankar V, Krishnamurthy A. Chemoprevention of oral cancer: Green tea experience[J]. J Nat Sci Biol Med, 2014, 5(1):3-7.

[6] Suganuma M, Saha A, Fujiki H. New cancer treatment strategy using combination of Green tea catechins and anticancer drugs[J]. Cancer Sci, 2011, 102(2):317-323.

[7] 刘凤琼, 鄢灵君, 陈法, 等. 饮茶与牙龈癌发病关系的病例对照研究[J]. 肿瘤防治研究, 2017, 44(2):138-141.

[8] Tao L, Park JY, Lambert JD. Differential prooxidative effects of the Green tea polyphenol, (-)-epigallocatechin-3-gallate, in normal and oral cancer cells are related to differences in sirtuin 3 signaling[J]. Mol Nutr Food Res, 2015, 59(2):203-211.

[9] Hamakawa H, Nakashiro K, Sumida T, et al. Basic evidence of molecular targeted therapy for oral cancer andsalivary gland cancer[J]. Head Neck, 2008, 30(6):800-809.

[10] Nagumo T, Ito D, Tsukamoto H, et al. STAT3 as a target of molecular targeting therapy for oral cancer: Cell-based screening using inhibitor screening kits[J]. Asian Journal of Oral and Maxillofacial Surgery, 2011, 23(4):167-171.

[11] Hassan M, Watari H, AbuAlmaaty A, et al. Apoptosis and molecular targeting therapy in cancer[J]. BioMed Research International, 2014, 2014:1-23.

[12] Jain M, Kasetty S, Sridhara SU, et al. Apoptosis and its significance in oral diseases: an update[J]. Journal of Oral Diseases, 2013:1-11.

[13] Bascones-martínez A, Rodríguez-gutierrez C, Rodríguez-gómez E, et al. Evaluation of p53, caspase-3, Bcl-2, and Ki-67 markers in oral squamous cell carcinoma and premalignant epithelium in a sample from Alava Province (Spain)[J]. Med Oral Patol Oral Cir Bucal, 2013, 18(6):e846-e850.

[14] Wang XY, Simpson ER, Brown KA. P53: protection against tumor growth beyond effects on cell cycle and apoptosis[J]. Cancer Res, 2015, 75(23): 5001-5007.

[15] 赵艳, 吴坤. 死亡分子Fas/CD95与细胞凋亡[J]. 癌变.畸变.突变, 2001, 13(1):55-58.

[16] Irimie AI, Braicu C, Zanoaga O, et al. Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer SSC-4 cells[J]. Onco Targets Ther, 2015, 8:461-470.

[17] Shin YS, Kang SG, Park JK, et al. Anti-cancer effect of (-)-epigallocatechin-3-gallate (EGCG) in head and neck cancer through repression of transactivation and enhanced degradation of β-catenin[J]. Phytomedicine, 2016, 23(12): 1344-1355.

[18] Siddiqui WA, Ahad A, Ahsan H. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update[J]. Arch Toxicol, 2015, 89(3):289-317.

[19] Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update[J]. Arch Toxicol, 2015, 89(6): 867-882.

[20] Lee JC, Chung LC, Chen YJ, et al. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells[J]. Cancer Lett, 2015, 360(2):310-318.

[21] Chang CM, Chang PY, Tu MG, et al. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2[J]. Oncol Rep, 2012, 28(5):1799-1807.

[22] Mayer IA, Arteaga CL.The PI3K/AKT pathway as a target for cancer teatment[J]. Annu Rev Med, 2016,67:11-28.

[23] 刘晓亮, 袁长吉, 庄平, 等. EGCG对口腔鳞癌细胞增殖及信号传导通路的影响[J]. 华中科技大学学报(医学版), 2013, 42(5):530-534.

[24] Vijayaraghavan S, Moulder S, Keyomarsi K, et al. Inhibiting CDK in cancer therapy: current evidence and future directions[J]. Target Oncol, 2018, 13(1):21-38.

[25] Massagué J. G1 cell-cycle control and cancer[J]. Nature, 2004, 432(7015):298-306.

[26] Jacob A., Prekeris R. The regulation of MMP targeting to invadopodia during cancer metastasis[J]. Front Cell Dev Biol, 2015, 3:4.

[27] Chen PN, Chu SC, Kuo WH, et al. Epigallocatechin-3 gallate inhibits invasion, epithelial-mesenchymal transition, and tumor growth in oral cancer cells[J]. J Agric Food Chem, 2011, 59(8):3836-3844.

[28] Egawa S, Iwai S, Iijima K, et al. Quantification of (?)-epigallocatechin-3-gallate inhibition of migration and invasion of oral squamous cell carcinoma cell lines using real-time cell analysis[J]. Showa Univ J Med Sci, 2015, 27(2):71-81.

[29] Lin HC, Wu CL, Chen YL, et al. High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells[J]. Clin Oral Investig, 2014, 18(4):1277-1284.

[30] 陈丽莉, 苏俭生. EGCG对舌鳞癌细胞CAL-27的EGFR、67LR及VEGF表达的影响[J]. 口腔颌面外科杂志, 2012, 22(4):238-241.

[31] Weng LX, Wang GH, Yao H, et al. Epigallocatechin gallate inhibits the growth of salivary adenoid cystic carcinoma cells via the EGFR/Erk signal transduction pathway and the mitochondria apoptosis pathway[J]. Neoplasma, 2017, 64(4):563-570.

[32] Du BW, Shim J. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer[J]. Molecules, 2016, 21(7):965.

[33] 陈震, 郭燕. E-cadherin和Vimentin在OSCC上皮-间质转化中的作用及表达[J]. 口腔医学研究, 2016, 32(8): 857-860.

[34] Lee SS, Tsai CH, Yu CC, et al. Correction: elevated snail expression mediates tumor progression in areca quid chewing-associated oral squamous cell carcinoma via reactive oxygen species[J]. PLoS One, 2013,8(7):e67985.

[35] Yu CC, Chen PN, Peng CY, et al. Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis[J]. Oncotarget, 2016, 7(15):20180-20192.

Please choose a citation manager

Content to export